Is enzalutamide generic?

Enzalutamide is the generic name for the trade name drug Xtandi®. In some cases, health care professionals may use the trade name Xtandi® when referring to the generic drug name enzalutamide.

When will enzalutamide go generic?

A generic version of XTANDI was approved as enzalutamide by ACTAVIS LABS FL INC on May 14th, 2021.

When does enzalutamide patent expire?

The terms of these issued XTANDI composition of matter patents expire in 2027 in the United States and in 2026 in Europe and Japan.

What class of drug is enzalutamide?

Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells.

How long can you take enzalutamide?

In addition to prolonged survival, patients given Enzalutamide showed meaningful improvement in other measures including PSA blood levels, an increase from 3.0 months to 8.3 months in time until PSA progression, and an increase from 2.9 months to 8.3 months in overall progression-free survival.

What does enzalutamide cost?

Enzalutamide is used to treat prostate cancer. Learn more about this drug here. This is a brand name drug and a generic may be available. The average cost for 16 Capsule(s), 40mg each, is $1,872.99.

What is the cost of enzalutamide?

The cost for Xtandi oral capsule 40 mg is around $12,825 for a supply of 120 capsules, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.

What are the side effects of enzalutamide?

Like all treatments, enzalutamide can cause side effects….Common side effects include:

• extreme tiredness (fatigue)
• headaches.
• hot flushes.
• high blood pressure.
• feeling nervous.
• problems with memory and concentration.
• dry or itchy skin.
• swelling of the breast area (gynaecomastia)

What is generic for xtandi?

Xtandi® is the trade name for the generic drug enzalutamide. In some cases, health care professionals may use the generic drug name enzalutamide when referring to the trade drug name Xtandi®.

Is enzalutamide a hormone?

Enzalutamide is among several hormone therapies that have been developed to prevent the androgen-fueled growth of castrate-resistant prostate cancers. This drug works by keeping androgens from binding to the androgen receptors on prostate cancer cells.

What is the treatment for enzalutamide?

If enzalutamide isn’t suitable for you, or if you choose not to have it, your doctor may offer you a different treatment. Possible treatments for advanced prostate cancer that has stopped responding to other types of hormone therapy include: abiraterone. chemotherapy (docetaxel or cabazitaxel)

How effective is enzalutamide?

At the interim analysis (after a median follow-up of approximately 22 months), 28 percent of men in the enzalutamide group had died, compared with 35 percent of men in the placebo group. Men who received enzalutamide experienced a 29 percent reduction in the risk of death compared with those who received placebo.

What kind of activity does enzalutamide have?

Enzalutamide is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity.

How does enzalutamide work on prostate cancer cells?

Enzalutamide. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level.

What is the half life of N-desmethyl-enzalutamide?

The activity of N-desmethyl-enzalutamide is similar to that of the parent compound. The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days).

How does enzalutamide therapy affect NF-κB2 / p52?

Resitance to enzalutamide therapy has been observed. This may occurred due to an upregulation of NF-κB2/p52. Enzalutamide is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity.